Skip to main content

Table 1 Details of fractionation regimes used in our study population (n = 115)

From: Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Fractionation regime

No. of cases (%)

6000 cGy/20 fractions

30 (26.1%)

5940 cGy/22 fractions

2 (1.7%)

6300 cGy/23 fractions

1 (0.9%)

6000 cGy/24 fractions

1 (0.9%)

6240 cGy/24 fractions

1 (0.9%)

6000 cGy/25 fractions

11 (9.6%)

6100 cGy/25 fractions

1 (0.9%)

6250 cGy/25 fractions

9 (7.8%)

6400 cGy/25 fractions

1 (0.9%)

6500 cGy/25 fractions

1 (0.9%)

7000 cGy/25 fractions

1 (0.9%)

6240 cGy/26 fractions

1 (0.9%)

6210 cGy/27 fractions

4 (3.5%)

6160 cGy/28 fractions

5 (4.3%)

6000 cGy/30 fractions

30 (26.1%)

6400 cGy/32 fractions

8 (7.0%)

6600 cGy/33 fractions

6 (5.2%)

7000 cGy/35 fractions

2 (1.7%)

  1. Note: The prescribed doses were given to gross tumor volume